# Reproducibility Reviewer

## Summary
The manuscript makes strong mechanistic claims about trans fatty acid metabolism and ferroptosis but lacks deposition of primary datasets (lipidomics, GC-FID, screening raw data) and analysis code, preventing independent reproduction of key figures. Procedural detail is sufficient for cell-based assays but incomplete for computational lipidomics pipelines and the FALCON screen, which relies on a prior publication without guaranteeing identical parameters. These gaps constitute a major reproducibility barrier for the load-bearing lipid remodeling and oxidation claims.

## Strengths
- Cell-based assays (viability, lipid droplets, flow cytometry) are described with sufficient reagent concentrations, timings, and instrument settings for an independent lab to replicate.
- Genetic and pharmacological perturbations (SCD OE/KO, inhibitors) include vendor catalog numbers and working concentrations, enabling direct reproduction of the mechanistic epistasis experiments.
- Lipidomics methods specify column, gradient, MS parameters, and internal standards, providing a template for targeted re-analysis if raw data were available.

## Weaknesses
- The central lipidomics evidence (Figures 5, 6, Supplementary Figures 4, 5) relies on data processed through an "in-house platform" at the UCLA Lipidomics Core with no deposition of raw files, peak tables, or processing code; without these, the phospholipid remodeling and hydroperoxide isomer quantifications cannot be verified or re-analyzed.
- The FALCON screen (Figure 1) references a prior publication (Wieder et al., 2023) for library preparation and screening protocol but does not confirm identical cell seeding densities, fatty acid conjugation batches, or Incucyte analysis parameters; the screening AUC normalization method is described in prose but not codified, so the hit list cannot be computationally reproduced.
- GC-FID fatty acid profiling (Figures 3, 6, Supplementary Figure 4) was performed at OmegaQuant with an "internal protocol" — no method details (derivatization, column, temperature program) or raw chromatograms are provided, making the trans-18:2 metabolite identification and quantification unverifiable.
- No data availability statement appears in the manuscript; neither raw nor processed datasets are deposited in a public repository (MetaboLights, PRIDE, GEO, Figshare, etc.), and "available on reasonable request" is not offered, so all load-bearing empirical data are inaccessible.
- Custom analysis pipelines for dose-response curves (AUC, lethal fraction), lipid droplet image quantification (Harmony software pipeline), and flow cytometry gating are not shared as code or versioned workflows, preventing exact replication of the quantitative outputs in Figures 1, 2, 4, 5.

## Questions
- Where are the raw and processed lipidomics datasets (LC-MS/MS hydroperoxide MRM data, shotgun lipidomics peak tables) deposited, and what is the accession/DOI?
- Is the "in-house platform" used for lipidomics data processing at UCLA available as versioned code (GitHub/Zenodo) or a container image?
- Can the FALCON screen raw Incucyte images and per-well lethal fraction time courses be provided, along with the exact normalization script used to compute AUC values?
- Are the GC-FID raw chromatograms and OmegaQuant's internal protocol (derivatization, column, gradient) available for the fatty acid profiling data?
- What are the exact Harmony high-content analysis pipeline settings (segmentation thresholds, spot detection parameters) used for lipid droplet quantification in Figure 4?